All In Biotech

Drug Trial Radar · NCT07908381

A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease

A Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelicapavir for Respiratory Syncytial Virus Infection in Adults Who Are at High Risk for Severe Disease

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 860 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

860

Planned (sponsor's estimate)

Start

Oct 19, 2026

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Zelicapavir is a novel orally administered non-fusion replication inhibitor of RSV that is being developed for the treatment of patients with RSV infection. This phase 2b/3 study will evaluate the efficacy and safety of zelicapavir compared with placebo in adults with RSV who are at high risk for severe disease. High-risk participants include those who are either ≥75 years of age or ≥18 years of age with COPD and/or CHF. Participants will be non-hospitalized adults who have up to 72 hours of respiratory tract infection symptoms and test positive for RSV.

Conditions

  • RSV

Interventions

  • zelicapavirDrug

    Zelicapavir 800mg, once daily for 7 days

  • PlaceboDrug

    Participants will take matching placebo, once daily for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to complete resolution of all 13 RSV symptoms as assessed by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) symptom scaleTime frame: Day 1 through Day 21

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • C&A Clinical Trials Corp

    Cape Coral, Florida · Recruiting

  • Continental Clinical Research, LLC

    Miami, Florida · Recruiting

  • PanAmerican Clinical Research

    Bluffton, South Carolina · Recruiting

  • PanAmerican Clinical Research - Brownville

    Brownsville, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.